Researchers at the University of Alabama at Birmingham and the University of Michigan have proposed 12 candidate aging rate indicators — molecular and physiological measures that differ consistently between normal mice and mice whose aging has been slowed by drugs, diet or genetics. Unlike biological age estimates, which record accumulated damage, these indicators are intended to register whether an organism has entered a slow-aging state in the present. If validated, they would shorten the timeline and cost of evaluating geroprotective compounds and clarify what slowed aging actually consists of.
Key Points
- Twelve candidate indicators distinguish slow-aging mice from normally aging controls
- Indicators measure current aging rate rather than accumulated biological age
- Authors caution that commercial biological age tests remain largely unvalidated
Longevity Analysis
The distinction between accumulated damage and current trajectory reshapes how any intervention should be judged. Consumer biological age scores report a position, not a direction, which leaves the central question — whether a protocol has altered the rate of decline — unanswered. The proposed panel spans mTORC1 and MEK/ERK signaling, brown fat thermogenic capacity, the balance between inflammatory and resolving macrophage populations, and hippocampal BDNF and neurogenesis markers, which is a reminder that slowed aging registers simultaneously in how the body produces energy, regulates temperature, defends itself and regenerates neural tissue. Until such measures are validated in humans, tracking interventions against functional endpoints and repeated measurement over years remains more informative than a single number.
Original published by Longevity.Technology, by Eleanor Garth.